This article was originally published in The Gray Sheet
Forge collaboration agreement under which Denmark firm Dako will develop an in vitro diagnostic breast cancer screening kit to detect over-expression of the HER2 growth factor receptor. Genentech is developing a humanized monoclonal antibody to HER2, Herceptin, for use as a possible breast cancer treatment. DAKO will gain rights to develop the immunohistochemical assay in return for royalties on worldwide sales...
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.
A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.